

**FOOD AND DRUG ADMINISTRATION (FDA)
Center for Biologics Evaluation and Research (CBER)
184th Meeting of the Vaccines and Related Biological Products Advisory
Committee
Silver Spring, MD
March 5, 2024
AGENDA**

Topic: The Committee will meet in open session to discuss and make recommendations on the selection of strains to be included in the influenza virus vaccines for the 2024 – 2025 influenza season.

Time	Presentation/Presenter
9:00am – 9:10am	<p><u>Opening Remarks: Call to Order and Welcome (10 Min)</u></p> <p>Hana El Sahly, M.D. Chair, VRBPAC Professor, Department of Molecular Virology and Microbiology Baylor College of Medicine</p>
9:10am – 9:30am	<p><u>Administrative Announcements, Roll Call, Introduction of Committee, Conflict of Interest Statement (20 Min)</u></p> <p>Sussan Paydar, Ph.D. Designated Federal Officer, VRBPAC Division Of Scientific Advisors and Consultants, CBER, FDA</p>
9:30am – 9:45am	<p><u>Introduction (15 Min)</u></p> <p>Jerry Weir, Ph.D. (10 Min) Director Division of Viral Products (DVP) Office of Vaccines Research and Review (OVRR) CBER, FDA</p> <p>Q & A: 5 min</p>
9:45am – 10:10am	<p><u>U.S. Surveillance (25 Min)</u></p> <p>Lisa Grohskopf, M.D., M.P.H. (20 Min) Medical Officer Epidemiology & Prevention Branch, Influenza Division Centers for Disease Control and Prevention (CDC)</p> <p>Q & A: 5 min</p>

**FOOD AND DRUG ADMINISTRATION (FDA)
Center for Biologics Evaluation and Research (CBER)
184th Meeting of the Vaccines and Related Biological Products Advisory
Committee
Silver Spring, MD
March 5, 2024
AGENDA**

10:10am – 11:20am	<p><u>Global Influenza Virus Surveillance and Characterization (70 Min including Q&A)</u></p> <p>Rebecca G. Kondor, Ph.D. (60 Min) Interim Director, WHO Collaborating Center for Surveillance Epidemiology and Control of Influenza Lead, Genomic Analysis Team NCIRD/Influenza Division/Virology Surveillance and Diagnosis Branch, Centers for Disease Control and Prevention (CDC)</p> <p>Q & A: 10 min</p>
11:20am – 11:30am	<p>Break (10 Min)</p>
11:30am – 11:55am	<p><u>DoD Influenza Surveillance and Mid-Season Vaccine Effectiveness (25 Min)</u></p> <p>Anthony Fries, Ph.D. (20 Min) DoD Global Respiratory Pathogen Surveillance Program Lead United States Air Force School of Aerospace Medicine</p> <p>Q & A: 5 min</p>
11:55am – 12:15pm	<p><u>Candidate Vaccine Strains & Potency Reagents (20 Min)</u></p> <p>Manju Joshi, Ph.D. (15 Min) Lead Biologist (Team Lead) Division of Biological Standards & Quality Control Office of Compliance and Biologics Quality CBER/FDA</p> <p>Q & A: 5 min</p>
12:15pm – 12:40pm	<p><u>Comments from Manufacturer Representative (25 min)</u></p> <p>David Greenberg, M.D. (20 Min) Interim Vaccines Medical Head North America Sanofi</p> <p>Q & A: 5 min</p>

**FOOD AND DRUG ADMINISTRATION (FDA)
Center for Biologics Evaluation and Research (CBER)
184th Meeting of the Vaccines and Related Biological Products Advisory
Committee
Silver Spring, MD
March 5, 2024
AGENDA**

12:40pm – 1:30pm	Lunch (50 Min)
1:30pm – 2:30pm	Open Public Hearing (60 Min)
2:30pm – 3:30pm	Committee Discussion, Recommendations, and Vote (60 Min)
3:30 pm	Adjourn the meeting - DFO